PRO MEDICUS LIMITED — Annual Report 2012

Aug 23, 2012

Appendix 4E Preliminary Final Report Rule 4.2A

Appendix 4E

Preliminary Final Report

1. Company details

1. Company details	1. Company details
Name of entity
Pro Medicus Limited
ABN or equivalentcompany referenceFinancial year ended(‘current period’)25 006 194 75230 June 20122. Results for announcement to the market			Financial year ended(‘previous period’)
			30 June 2011
ASXListingRules**Ref **				2011A$’000
2.1	Revenue from continuing operationsRevenue from discontinued operationsTotal Revenue% change up/(down) of revenue from ordinary activities fromthe previous corresponding period.			11,3793,01314,326Up2.56%
2.2	Profit after tax attributable to members% change up/(down) of Profit/(Loss) from ordinary activitiesafter tax attributable to members from the previouscorresponding period.			1,791Up256.1%
2.3	Net Profit for the period attributable to members			1,791Up256.1%
	% change up/(down) of Net Profit/(Loss) for the periodattributable to members from the previous correspondingperiod.

2.4	Dividends (distributions)	Amount persecurity	Fully Frankedamount persecurity
	Franked dividend amount per securityFinal DividendInterim dividend	1.0 cents0.5 cents	1.0 cents0.5 cents
2.5	Record date for Final dividends	14 September 2012
	Payment date for Final dividends	5 October 2012

Appendix 4E Page 1

Appendix 4E Preliminary Final Report

			Appendix 4EPreliminary Final Report	Appendix 4EPreliminary Final Report	Appendix 4EPreliminary Final Report
	26		AustraliaThe group employs 28 people in Australia who undertake research and development of Pro Medicusproducts as well as sales and service/support functions.The group’s Australian revenue declined over the period by 6.75% due to delays in commercialisationof the company’s new RIS technology platform to market.Promedicus.net, the company’s e-health offering, continued to hold its strong market positionrecording revenue of $1.75 million despite increasing competition.North AmericaThe group employs 10 people in North America to fulfil the sales marketing and professional servicesroles. Revenue from North America declined by 3.8% compared to the previous year. The companymade a number of changes in the group’s US management and operations during the past yearincluding a significant decrease in overall running costs. The company believes these changes willhave a positive impact on the performance of the North American division.EuropePro Medicus established a presence in Europe with the acquisition of Visage Imaging GmbH in lateJanuary 2009. The group has 41 employees in its Berlin office who undertake research anddevelopment of Visage Imaging products worldwide as well as sales, marketing and service/supportfunctions for the group's European operations. Revenue from our European operations increased by24.6% compared to the previous year.FinancialsFull year revenue from continuing operations, rose from $11.18 million to $11.38 million, an increaseof 1.8% with net margin as defined by profit before tax to revenue from operating activities rising from(9.0%) to 9.0%.Profit after tax for the period was $1.79 million an increase of 256.1% from the previous year reflectinghigher margins and decreased ongoing costs.Shareholder ReturnsThe directors are confident that the holdings of reserve cash is sufficient to underpin the developmentand expansion needs of the company as the business looks to increase its penetration of existingmarkets and new product development.
.3.4.5.	.		The group employs 28 people in Australiaproducts as well as sales and service/suppThe group’s Australian revenue declined ovof the company’s new RIS technology platPromedicus.net, the company’s e-healthrecording revenue of $1.75 million despite iNorth AmericaThe group employs 10 people in North Amroles. Revenue from North America declinemade a number of changes in the group’sincluding a significant decrease in overall rhave a positive impact on the performanceEuropePro Medicus established a presence in EurJanuary 2009. The group has 41 employedevelopment of Visage Imaging products wfunctions for the group's European operatio24.6% compared to the previous year.FinancialsFull year revenue from continuing operationof 1.8% with net margin as defined by profit(9.0%) to 9.0%.Profit after tax for the period was $1.79 millhigher margins and decreased ongoing cosShareholder ReturnsThe directors are confident that the holdingand expansion needs of the company as thmarkets and new product development.	who undertake research and development of Pro Meort functions.er the period by 6.75% due to delays in commerciaform to market.offering, continued to hold its strong marketncreasing competition.erica to fulfil the sales marketing and professional sed by 3.8% compared to the previous year. The comUS management and operations during the past yeaunning costs. The company believes these changesof the North American division.ope with the acquisition of Visage Imaging GmbH ines in its Berlin office who undertake research andorldwide as well as sales, marketing and service/suns. Revenue from our European operations increass, rose from $11.18 million to $11.38 million, an incbefore tax to revenue from operating activities risinion an increase of 256.1% from the previous year rets.s of reserve cash is sufficient to underpin the develoe business looks to increase its penetration of existi
	3.		Statement of Comprehensive IncPlease refer to the Statement of ComprStatements.	omeehensive Income in the attached Financial
	4.		Statement of Financial PositionPlease refer to the Statement of Financ	ial Position in the attached Financial Statemen	ts.
	5.		Statement of cash flowsPlease refer to the Statement of cash fl	ows in the attached Financial Statements.
				Appendix 4E Pag

Appendix 4E Page 2

Appendix 4E Preliminary Final Report

6.	Details of Dividends2012$’0002011$’000Final DividendA Final Dividend of 1.0 cents (2011: Nil) per share fullyfranked will be paid on 5thOctober 2012.1,002NilCurrent Year InterimAn interim dividend of 0.50 cents (2011: Nil) per sharefully franked was paid on 21 March 2012.$501-No foreign sourced dividend or distribution is included in either the interim or finaldividends.
7.	Dividend or Distribution reinvestment plansThere are no dividend or distribution reinvestment plans in operation.
8.	Statement of Retained EarningsPlease refer to Statement of Changes in Equity in the attached Financial Statements.
9.	Net Tangible Assets per security20122011Net Tangible Assets per security$0.05$0.02
10.	Details of entities over which control has been gained or lost during theperiodThere are no entities over which control has been gained or lost during the period
11.	Associates and joint venture entitiesThere are no associates or joint venture entities
12.	Other significant information needed by an investor to make an informedassessment of the entity’s financial performance and financial position.Please refer to section 2.6
13.	Foreign Entity accounting standardsAustralian Accounting Standards & International Financial Reporting Standards

Appendix 4E Page 3

Appendix 4E Preliminary Final Report

14. Commentary on results for the period. The earnings per security and the nature of any dilution aspects . Please refer to Note 9 of the attached Financial Statements.

Returns to shareholders including distributions and buy backs. Please refer to Note 10 of the attached Financial Statements.

Significant features of operating performance . Please refer to section 2.6.

The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.

Discussion of trends in performance. Please refer to section 2.6.

15. Audit Statement

This report is based on accounts to which one of the following applies. (Tick one)

 The +accounts have been  The[+] accounts have been subject to audited. review.  The +accounts are in the  The[+] accounts have not yet been process of being audited. audited or reviewed.

Sign here:

Date: 24 August 2012

==> picture [198 x 64] intentionally omitted <==

Print name: Sam Hupert Chief Executive Officer

Appendix 4E Page 4